![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assay Development and Compound Profiling (C.W., T.K.), Departments of Biochemical and Analytical Pharmacology (S.J.) and Medicinal Chemistry (W.K.), GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina
Abstract
4-{[4-({(3R)-1-Butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenyl]oxy}benzoic acid hydrochloride (873140) is a potent noncompetitive allosteric antagonist of the CCR5 receptor (pKB = 8.6 ± 0.07; 95% CI, 8.5 to 8.8) with concomitantly potent antiviral effects for HIV-1. In this article, the receptor-based mechanism of action of 873140 is compared with four other noncompetitive allosteric antagonists of CCR5. Although (Z)-(4-bromophenyl){1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidin-4-yl}methanone O-ethyloxime (Sch-C; SCH 351125), 4,6-dimethyl-5-{[4-methyl-4-((3S)-3-methyl-4-{(1R)-2-(methyloxy)-1-[4-(trifluoromethyl)phenyl]ethyl}-1-piperazinyl)-1-piperidinyl]carbonyl}pyrimidine (Sch-D; SCH 417,690), 4,4-difluoro-N-((1S)-3-{(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenyl-propyl)cyclohexanecarboxamide (UK-427,857), and N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclo-hepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium chloride (TAK779) blocked the binding of both chemokines 125I-MIP-1
(also known as 125I-CCL3, 125I-LD78) and 125I-RANTES (125I-CCL5), 873140 was an ineffectual antagonist of 125I-RANTES (regulated on activation normal T cell expressed and secreted) binding (but did block binding of 125I-MIP-1). Furthermore, 873140 blocked the calcium response effects of CCR5 activation by CCL5 (RANTES) (as did the other antagonists), indicating a unique divergence of blockade of function and binding with this antagonist. The antagonism of CCR5 by 873140 is saturable and probe-dependent, consistent with an allosteric mechanism of action. The blockade of CCR5 by 873140 was extremely persistent with a rate constant for reversal of <0.004 h- 1 (t1/2 > 136 h). Coadministration studies of 873140 with the four other allosteric antagonists yielded data that are consistent with the notion that all five of these antagonists bind to a common allosteric site on the CCR5 receptor. Although these ligands may have a common binding site, they do not exert the same allosteric effect on the receptor, as indicated by their differential effects on the binding of 125I-RANTES. This idea is discussed in terms of using these drugs sequentially to overcome HIV viral resistance in the clinic.
Address correspondence to: Terry Kenakin, Assay Development and Compound Profiling, GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709. Email: Terry.P.Kenakin{at}gsk.com
This article has been cited by other articles:
|
|
 |
|
  J. F. Demarest, S. S. Sparks, K. Schell, S. Shibayama, C. B. McDanal, L. Fang, K. K. Adkison, A. Shachoy-Clark, and S. C. Piscitelli In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti-HIV Activity of Aplaviroc J. Clin. Pharmacol., October 1, 2008; 48(10): 1179 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Kenakin Seven Transmembrane Receptors as Nature's Prototype Allosteric Protein: De-emphasizing the Geography of Binding Mol. Pharmacol., September 1, 2008; 74(3): 541 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. N. Tsibris, M. Sagar, R. M. Gulick, Z. Su, M. Hughes, W. Greaves, M. Subramanian, C. Flexner, F. Giguel, K. E. Leopold, et al. In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject J. Virol., August 15, 2008; 82(16): 8210 - 8214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kondru, J. Zhang, C. Ji, T. Mirzadegan, D. Rotstein, S. Sankuratri, and M. Dioszegi Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists Mol. Pharmacol., March 1, 2008; 73(3): 789 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Nolan, A. P. O. Jordan, and J. A. Hoxie Effects of Partial Deletions within the Human Immunodeficiency Virus Type 1 V3 Loop on Coreceptor Tropism and Sensitivity to Entry Inhibitors J. Virol., January 15, 2008; 82(2): 664 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lin, A. Bertolotti-Ciarlet, B. Haggarty, J. Romano, K. M. Nolan, G. J. Leslie, A. P.-O. Jordan, C.-c. Huang, P. D. Kwong, R. W. Doms, et al. Replication-Competent Variants of Human Immunodeficiency Virus Type 2 Lacking the V3 Loop Exhibit Resistance to Chemokine Receptor Antagonists J. Virol., September 15, 2007; 81(18): 9956 - 9966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Gonsiorek, X. Fan, D. Hesk, J. Fossetta, H. Qiu, J. Jakway, M. Billah, M. Dwyer, J. Chao, G. Deno, et al. Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 477 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Jensen, R. Nygaard, S. Thiele, A. Elder, G. Zhu, R. Kolbeck, S. Ghosh, T. W. Schwartz, and M. M. Rosenkilde Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8 Mol. Pharmacol., August 1, 2007; 72(2): 327 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ji, J. Zhang, M. Dioszegi, S. Chiu, E. Rao, A. deRosier, N. Cammack, M. Brandt, and S. Sankuratri CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor Mol. Pharmacol., July 1, 2007; 72(1): 18 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, E. Rao, M. Dioszegi, R. Kondru, A. DeRosier, E. Chan, S. Schwoerer, N. Cammack, M. Brandt, S. Sankuratri, et al. The Second Extracellular Loop of CCR5 Contains the Dominant Epitopes for Highly Potent Anti-Human Immunodeficiency Virus Monoclonal Antibodies Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1386 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gaibelet, T. Planchenault, S. Mazeres, F. Dumas, F. Arenzana-Seisdedos, A. Lopez, B. Lagane, and F. Bachelerie CD4 and CCR5 Constitutively Interact at the Plasma Membrane of Living Cells: A CONFOCAL FLUORESCENCE RESONANCE ENERGY TRANSFER-BASED APPROACH J. Biol. Chem., December 8, 2006; 281(49): 37921 - 37929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kenakin, S. Jenkinson, and C. Watson Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 710 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Murga, M. Franti, D. C. Pevear, P. J. Maddon, and W. C. Olson Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3289 - 3296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Chan, G. Heilek-Snyder, N. Cammack, S. Sankuratri, and C. Ji Development of a Moloney Murine Leukemia Virus-Based Pseudotype Anti-HIV Assay Suitable for Accurate and Rapid Evaluation of HIV Entry Inhibitors J Biomol Screen, September 1, 2006; 11(6): 652 - 663. [Abstract] [PDF]
|
|
|
|
 |
|
 M. M. Lederman, A. Penn-Nicholson, M. Cho, and D. Mosier Biology of CCR5 and its role in HIV infection and treatment. JAMA, August 16, 2006; 296(7): 815 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Johnson, I. H. Song, K. K. Adkison, J. Borland, L. Fang, Y. Lou, M. M. Berrey, A. N. Nafziger, S. C. Piscitelli, and J. S. Bertino Jr Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail. J. Clin. Pharmacol., May 1, 2006; 46(5): 577 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ji, J. Zhang, N. Cammack, and S. Sankuratri Development of a Novel Dual CCR5-Dependent and CXCR4-Dependent Cell-Cell Fusion Assay System with Inducible gp160 Expression J Biomol Screen, February 1, 2006; 11(1): 65 - 74. [Abstract] [PDF]
|
|
|
|
|
|
P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, et al. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4721 - 4732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Price, G. L. Baillie, A. Thomas, L. A. Stevenson, M. Easson, R. Goodwin, A. McLean, L. McIntosh, G. Goodwin, G. Walker, et al. Allosteric Modulation of the Cannabinoid CB1 Receptor Mol. Pharmacol., November 1, 2005; 68(5): 1484 - 1495. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
